Skip to content

Dissecting How Peripheral Lymphocytes Are Lost During Sepsis

Dissecting How Peripheral Lymphocytes Are Lost During Sepsis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03289312
Acronym
SLL
Enrollment
54
Registered
2017-09-20
Start date
2018-01-11
Completion date
2018-12-31
Last updated
2017-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

sepsis, lymphocyte

Brief summary

There is an observational, clinical study. We recruit sepsis patients to investigate what drives peripheral lymphocyte loss in sepsis.

Detailed description

There is an observational, clinical study. We recruit patients with diagnosis of new onset sepsis within 24h, collect and record clinical characteristics: ①Demography data,diagnosis, admission source, infection source, APACHE II,SOFA scores;②Endotoxin levels and PaO2 measured;③Immune and systemic inflammatory indicators:T, RR, WBC, ALC, etc.;④Complicated organs dysfunctions: duration and therapy;⑤Incidence of ICU-acquired infection and prognosis.The blood samples were collected for apoptosis,necrosis,autophagy,pyroptosis measurements.The aim of this study is to investigate how peripheal lymphocyte loss relates to outcome and the mechanisms of peripheal lymphocyte loss in different condition.

Interventions

None listed

Sponsors

Southeast University, China
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Health volunteers

Exclusion criteria

* History of tumor, hematological or immunological disease, and treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization.

Design outcomes

Primary

MeasureTime frameDescription
lymphocyte lossday of inclussion and 7th day after inclussionratios of T cells loss by different mechanism in different subgroups

Secondary

MeasureTime frameDescription
prognosis28-day after inclussion28-day prognosis:survive or not
Complicated organ dysfunctionduring 28 days after inclussionduration and surpport therapy

Countries

China

Contacts

Primary ContactMing Xue, MD
xueming0304@126.com08615195971003

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026